Latest News
IMPACT Therapeutics grants Pharmanovia exclusive rights to senaparib across 66 countries
31 July 2026 - Hong Kong-based biotechnology company IMPACT Therapeutics, Inc. (HKG: 7630) announced on Friday that it has entered an exclusive partnership with Pharmanovia, granting the global specialty pharmaceutical company rights to manufacture, ...
Datroway approved in EU for first-line metastatic triple-negative breast cancer
31 July 2026 - Datroway (datopotamab deruxtecan), jointly developed by Japanese healthcare company Daiichi Sankyo Co Ltd (TYO:4568) and British-Swedish biopharmaceutical company AstraZeneca plc (STO:AZN) (LON:AZN) (NYSE:AZN), has received European Un...
Karyopharm reports topline Phase 3 trial results in endometrial cancer
31 July 2026 - Karyopharm Therapeutics Inc (Nasdaq:KPTI), a commercial-stage pharmaceutical company developing novel cancer therapies, on Thursday announced topline results from its Phase 3 XPORT-EC-042 trial evaluating XPOVIO (selinexor) as a mainte...
Proteotype unveils Alchemi platform for blood-based multi-cancer test Enlighten
31 July 2026 - Portugal-based Proteotype Diagnostics Unipessoal LDA on Thursday unveiled Alchemi, its proprietary data and clinical workflow platform being developed for Enlighten, the company's investigational blood-based multi-cancer test.Enli...
Kaigene and Taisho enter exclusive KG006 licensing agreement in Japan
31 July 2026 - US-based biotechnology company Kaigene Inc announced on Thursday that it has entered into an exclusive licensing agreement with Japanese pharmaceutical company Taisho Pharmaceutical Co Ltd for the exclusive development and commercialis...